The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Official Title: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
Study ID: NCT02817633
Brief Summary: This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
GSK Investigational Site, Goodyear, Arizona, United States
GSK Investigational Site, Scottsdale, Arizona, United States
GSK Investigational Site, Tucson, Arizona, United States
GSK Investigational Site, Tucson, Arizona, United States
GSK Investigational Site, Encinitas, California, United States
GSK Investigational Site, Fountain Valley, California, United States
GSK Investigational Site, Los Angeles, California, United States
GSK Investigational Site, Los Angeles, California, United States
GSK Investigational Site, Whittier, California, United States
GSK Investigational Site, Aurora, Colorado, United States
GSK Investigational Site, Aurora, Colorado, United States
GSK Investigational Site, Denver, Colorado, United States
GSK Investigational Site, Denver, Colorado, United States
GSK Investigational Site, New Haven, Connecticut, United States
GSK Investigational Site, Washington, District of Columbia, United States
GSK Investigational Site, Jacksonville, Florida, United States
GSK Investigational Site, Miami Beach, Florida, United States
GSK Investigational Site, Sarasota, Florida, United States
GSK Investigational Site, Tampa, Florida, United States
GSK Investigational Site, Atlanta, Georgia, United States
GSK Investigational Site, Augusta, Georgia, United States
GSK Investigational Site, Arlington Heights, Illinois, United States
GSK Investigational Site, Chicago, Illinois, United States
GSK Investigational Site, Niles, Illinois, United States
GSK Investigational Site, Iowa City, Iowa, United States
GSK Investigational Site, Wichita, Kansas, United States
GSK Investigational Site, Louisville, Kentucky, United States
GSK Investigational Site, Pikeville, Kentucky, United States
GSK Investigational Site, Rockville, Maryland, United States
GSK Investigational Site, Boston, Massachusetts, United States
GSK Investigational Site, Detroit, Michigan, United States
GSK Investigational Site, Rochester, Minnesota, United States
GSK Investigational Site, Hackensack, New Jersey, United States
GSK Investigational Site, Bronx, New York, United States
GSK Investigational Site, New York, New York, United States
GSK Investigational Site, Cincinnati, Ohio, United States
GSK Investigational Site, Cleveland, Ohio, United States
GSK Investigational Site, Toledo, Ohio, United States
GSK Investigational Site, Eugene, Oregon, United States
GSK Investigational Site, Portland, Oregon, United States
GSK Investigational Site, Bethlehem, Pennsylvania, United States
GSK Investigational Site, Pittsburgh, Pennsylvania, United States
GSK Investigational Site, Charleston, South Carolina, United States
GSK Investigational Site, Greenville, South Carolina, United States
GSK Investigational Site, Nashville, Tennessee, United States
GSK Investigational Site, Austin, Texas, United States
GSK Investigational Site, Dallas, Texas, United States
GSK Investigational Site, Fort Worth, Texas, United States
GSK Investigational Site, Houston, Texas, United States
GSK Investigational Site, Houston, Texas, United States
GSK Investigational Site, Longview, Texas, United States
GSK Investigational Site, McAllen, Texas, United States
GSK Investigational Site, San Antonio, Texas, United States
GSK Investigational Site, San Marcos, Texas, United States
GSK Investigational Site, Temple, Texas, United States
GSK Investigational Site, Tyler, Texas, United States
GSK Investigational Site, Weslaco, Texas, United States
GSK Investigational Site, Fairfax, Virginia, United States
GSK Investigational Site, Kennewick, Washington, United States
GSK Investigational Site, Puyallup, Washington, United States
GSK Investigational Site, Tacoma, Washington, United States
GSK Investigational Site, Madison, Wisconsin, United States
GSK Investigational Site, Daegu, , Korea, Republic of
GSK Investigational Site, Seongnam-si, Gyeonggi-do, , Korea, Republic of
GSK Investigational Site, Seoul, , Korea, Republic of
GSK Investigational Site, Seoul, , Korea, Republic of
GSK Investigational Site, Seoul, , Korea, Republic of
GSK Investigational Site, Seoul, , Korea, Republic of
GSK Investigational Site, Palma de Mallorca, Islas Baleares, Spain
GSK Investigational Site, Madrid, Navarra, Spain
GSK Investigational Site, Barcelona, , Spain
GSK Investigational Site, Barcelona, , Spain
GSK Investigational Site, Girona, , Spain
GSK Investigational Site, Jerez de la Frontera, , Spain
GSK Investigational Site, L'Hospitalet De Llobregat, , Spain
GSK Investigational Site, Las Palmas De Gran Canaria, , Spain
GSK Investigational Site, Madrid, , Spain
GSK Investigational Site, Madrid, , Spain
GSK Investigational Site, Madrid, , Spain
GSK Investigational Site, Majadahonda (Madrid), , Spain
GSK Investigational Site, Málaga, , Spain
GSK Investigational Site, Pamplona, , Spain
GSK Investigational Site, Santander, , Spain
GSK Investigational Site, Sevilla, , Spain
GSK Investigational Site, Valencia, , Spain
GSK Investigational Site, Valencia, , Spain
Name: GSK Clinical Trials
Affiliation: GlaxoSmithKline
Role: STUDY_DIRECTOR